Home » Authors » Catherine Hollingsworth

Articles by Catherine Hollingsworth

ConjuChem Wants to Recapitalize with $35M from New Investors

May 19, 2010

By Catherine Hollingsworth

NewCo News: ElexoPharm's First License Deal Worth up to $41.6M from Merck

May 18, 2010

By Catherine Hollingsworth and Cormac Sheridan

Pharmasset Hopes to Raise $87.9M to Fund HCV Trials

May 17, 2010

By Catherine Hollingsworth

NicOx Shares Take a Tumble; Firm Ponders Approval Path

May 14, 2010

By Catherine Hollingsworth

Sequenom Seeks to Right Itself With $51.5M Share Placement

May 13, 2010

By Catherine Hollingsworth

CureVac Raises $32.25M for mRNA-Based Vaccine Trials

May 12, 2010

By Catherine Hollingsworth

Amorfix, Epitomics Partnering on Cancer Antibody Targets

May 12, 2010

By Catherine Hollingsworth

CureVac Raises $32.25M for mRNA-Based Vaccine Trials

May 11, 2010

By Catherine Hollingsworth

ImmunoGen Seeking $67.4M to Advance Cancer Compounds

May 10, 2010

By Catherine Hollingsworth

Avanir Raising Funds to Push Zenvia Toward the Finish Line

May 7, 2010

By Catherine Hollingsworth

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for July 2, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for July 2, 2025.
Unnatural Products joins Argenx in a $1.5B macrocyclic deal
BioWorld
Unnatural Products Inc. notched another collaboration by signing on with Argenx SE in a multitarget research collaboration. Unnatural Products, which is getting...
Exercise-mimicking compound offers alternative to GLP-1 therapies
BioWorld
An experimental drug for treating diabetes and obesity has been shown to lower blood sugar levels and increase fat burning. It is a β2-adrenergic receptor (β2AR)...
CMS eyes competitive bidding for CGMs, insulin pumps
BioWorld MedTech
The U.S. Centers for Medicare & Medicaid Services posted the draft home health rule for calendar year 2026, which includes a proposal to subject continuous...